胰高糖素样肽-1受体激动剂(GLP-1RA)在"三高"管控中的治疗作用

The therapeutic effect of glucagon like peptide-1 receptor agonist(GLP-1RA)in the management of"three high"

目的 讨论胰高糖素样肽-1受体激动剂(GLP-1RA)在"三高"管控中的治疗作用.方法 从一例"三高"合并肥胖、肾功能减退的患者社区住院应用GLP-1RA的用药体会,结合文献指南,分析GLP-1RA在"三高"管控中的治疗作用.结果 GLP-1RA在"三高"共管中可显著降低主要心血管事件的发生率和全因死亡率.结论 GLP-1RA有助于对"三高"的管控.对于合并动脉粥样硬化性心血管疾病(ASCVD)/高危因素,心衰、慢性肾脏病的T2DM患者,应选择经证实具有心血管获益的GLP-1RA.

Objective To discuss the therapeutic role of the glucagon-like peptide-1 receptor agonist(GLP-1RA)in the three high"control.Methods The therapeutic effect of CLP-IRA in the control of"three high"was analyzed from the medication experience of GLP-IRA combined with the literature guidelines.Results GLP-IRA significantly reduced the incidence of major cardiovascular events and all-cause mortality at the three high levels.Conclusion GLP-IRA helps to improve the control of the three high levels".For the combined ASCVD/high-risk factors,heart failure,chronic kidney disease In patients with T2DM,the GLP-IRA with a proven cardiovascular benefit should be selected.